Systemic inflammation is associated with impaired wound healing in diabetes mellitus (DM) patients. Using immunohistochemistry techniques, the authors investigated changes in skin inflammation and skin blood vessels in human and experimental diabetes. Comparing to the non-DM human subjects, the total number of inflammatory cells per biopsy and the number of inflammatory cells around blood vessels, a strong indication of inflammation, were higher in DM subjects irrespective of their risk for developing diabetic foot ulcer. Inflammatory cell infiltration was robustly increased in all DM animal models compared with their non-DM controls. The number and density of blood vessels and CD31 positive proliferating endothelial cells around preexisting skin vessels was also higher in the DM patients. However, there were no differences in the skin blood flow between the non-DM and DM subjects. The number of skin blood vessels was also increased in the DM animals; however, these differences were less obvious than the ones observed for inflammatory cells. We conclude that skin inflammation and skin blood vessel density is increased in diabetic human subjects and in rodent and rabbit models of diabetes.
Introduction
Foot ulcers and impaired wound healing are common problems in diabetes as they can affect 15% of all diabetes mellitus (DM) patients during their lifespan, resulting in more than 70 000 lower extremity amputations per year in the United States alone. 1, 2 As the diabetes pandemic continues unabated and diabetic patients live longer, it should be expected that the incidence of diabetic foot problem would increase over the next few decades.
Recent studies by our group have shown that systemic inflammation is associated with impaired wound healing in DM patients. 3 In addition, we have shown that skin biopsies from both the forearm and dorsum of the foot of DM patients have increased inflammatory cell infiltration when comparing with non-DM subjects. However, there is little information regarding the blood vessel density in the skin of DM patients. Furthermore, it is not known whether the skin changes observed in DM patients are also present in various experimental animal models of diabetes commonly used in wound healing studies. Given the lack of satisfactory animal models, the possible similarities and differences between human and experimental diabetes may prove very helpful in designing mechanistic studies in the future.
In the present study, we used immunohistochemistry techniques to compare the inflammatory cell infiltration and blood vessel density changes between non-DM and DM rabbits, rats, and mice. We also compared the animal study results with the results obtained from the forearm and dorsal foot skin biopsies of non-DM and DM human subjects. biopsies were obtained from a well-characterized cohort of healthy control (non-DM) subjects and diabetic (DM) patients who had participated in a prospective study involving investigation of the mechanisms of wound healing impairment in diabetes. Detailed information regarding this group is provided elsewhere. 3 Foot skin biopsies. For the present study, we used discarded skin specimens that were collected for the same study as the forearm skin biopsies. Hematoxylin and eosin (H&E) and CD31 immunohistochemistry staining was performed in all biopsies. In our previous study, round cells were confirmed as being inflammatory cells by staining for CD45RO, a marker of lymphocytes, and factor XIIIa, a marker of dermal dendrocytes. 3 Skin blood flow was monitored using a Laser Doppler Perfusion Imager (Lisca PIM 2.0, Lisca Development AB, Linkoping, Sweden) as previously described. 4 In brief, a 2 × 2 cm skin area was scanned after all subjects were acclimatized in a room with controlled temperature for 30 minutes. The skin area was the same that was used to perform skin biopsies after skin blood flow measurements were completed. The protocol was approved by the institutional review board of the Beth Israel Deaconess Medical Center. All participants gave written informed consent.
Animals
Rabbit model. New Zealand White male rabbits weighing 3.0 to 3.2 kg were obtained from Millbrook Farms (Amherst, MA). Six rabbits were made diabetic by injecting 2 doses of 50 mg/kg of alloxan monohydrate via the marginal ear vein, 48 hours apart. Seven rabbits in the non-DM group received vehicle alone (saline). Rabbits with fasting blood glucose more than 250 mg/dL were considered diabetic. Ten days after alloxan administration, rabbits were anesthetized using ketamine (25 mg/kg intramuscularly) and xylazine (3 mg/kg intramuscularly) and skin biopsies from the ear were obtained using a 6-mm punch biopsy.
Rat model. Eight-week old male Sprauge-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA). Ten rats were made diabetic by administering a single dose of streptozotocin (STZ; 60 mg/kg, intraperitoneally) in citrate buffer (0.1 M). The non-DM group (9 rats) received equal volume of vehicle alone. Rats with fasting blood glucose more than 250 mg/dL were considered diabetic. Six to eight weeks after STZ treatment, rats were anesthetized using ketamine (35 mg/kg intramuscularly) and xylazine (2.5 mg/kg intramuscularly), and 6-mm fullthickness skin punch biopsies were obtained from the shaved dorsum of the rat.
Mouse model. C57BL6 and WBB6F1 male mice were obtained from Jackson Laboratories (Bar Harbor, ME). Nine 8-week-old mice were made diabetic by administering 50 mg/kg STZ (intraperitoneally qid for 5 consecutive days) in citrate buffer (0.1 M). In the non-DM group, 9 mice were treated with vehicle alone. Fasting blood glucose was monitored a week after the last injection, and mice with blood glucose more than 250 mg/dL were considered diabetic. Six to 8 weeks after STZ treatment, mice were anesthetized using ketamine (100 mg/kg intraperitoneally) and xylazine (5 mg/kg intraperitoneally), and 6-mm full-thickness skin punch biopsies were obtained from the shaved dorsum of the mice. All animal studies were conducted in accordance with Institutional Animal Care and Use Committeeapproved protocols.
Tissue Analysis
Human specimens. Biopsies were embedded in optimal cutting temperature compound (OCT) and frozen in liquid nitrogen immediately after collection, stored at −80°C, and were analyzed by a pathologist with expertise in dermatopathology (AK). Five-micrometer sections were cut and fixed in acetone immediately before staining. To study skin inflammation, sections were stained with H&E according to standard protocols for cryosections. The number of inflammatory round cells was counted in each biopsy. To evaluate skin blood vessel density, immunohistochemistry for CD31 was performed using a mouse monoclonal antibody (JC70A, Abcam, Cambridge, MA), as described elsewhere. 3 CD31 is commonly used as a marker for endothelial cells. In this study, immunohistochemistry for CD31 was performed with the purpose of identifying both proliferating endothelial cells and skin blood vessels. Endothelial cells were characterized as proliferating when they were observed as single, CD31-positive cells that were located in the proximity of preexisting blood vessels but did not have a lumen. 5 Animal samples. Skin samples were fixed in 10% formalin immediately after collection and embedded in paraffin blocks. Six-micrometer sections were cut and stained with H&E according to standard techniques for paraffin sections. Analysis was performed by an observer (AT) who was unaware of the group each biopsy belonged under the supervision of the pathologist (AK). Round inflammatory cells and blood vessels were counted in 4 different visual fields per section (400×). To avoid the risk of misclassifying other cell types as inflammatory, which in most cases are transversely cut fibroblasts/fibrocytes that may appear round, we mainly counted round cells with a diameter of 6 to 12 µm in the proximity of blood vessels where inflammatory cells are first observed during the inflammatory process. We also took into consideration additional subtle morphological details, and we excluded cells with characteristics that are compatible with fibroblasts/fibrocytes (diameter 12-15 µm, bland looking nucleus). Immunohistochemistry for CD31 was performed using a purified rat monoclonal antibody (BD 550274, BD Biosciences, San Jose, CA) for mouse, a rabbit polyclonal antibody (250590, ABBiotech San Diego, CA) for rat, and a rat monoclonal antibody (AB 56299, Abcam, Cambridge, MA) for rabbit specimens. Briefly, sections were deparaffinized, hydrated, and subjected to proteinase K treatment for antigen retrieval. Overnight incubation with the primary antibody at 4°C was followed by biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) and avidin-biotin-peroxidase complex by using the Vectastain elite ABC rat kit and diaminobenzidine (DAB) as chromogen development (Vector Laboratories). The number of CD31-positive endothelial cells and/or the number of blood vessels were counted in 4 different highpower fields per section (400×). Results are expressed as average number/visual field.
Statistical Analysis
Data analysis was performed using Minitab (Minitab, State College, PA). Analysis of variance (ANOVA) and the t test were employed for the comparisons among the groups for normally distributed data. Nonparametrical data were analyzed through Kruskal-Wallis analysis of variance. The Pearson test was used to for the calculation of the correlation coefficient. Data are presented as mean ± standard deviation.
Results

Human Forearm Biopsies
We examined the forearm skin biopsies from 12 healthy non-DM subjects (age 60 ± 6 years, 4 males, group C). DM subjects were divided into 2 groups, 10 diabetic subjects with neuropathy not severe enough to be at risk of developing foot ulceration (low-risk; age 56 ± 9 years, 4 males, 3 type 1 diabetes, diabetes duration 12 ± 13 years, group D) and 50 neuropathic diabetic subjects at risk of foot ulceration (high-risk; age 56 ± 8 years, 37 males, 21 type 1 diabetes, diabetes duration 22 ± 14 years, group DN). Diabetes duration was 32 ± 13 years in type 1 DM and 13 ± 9 in type 2 DM patients (P < .001). There were no other major differences in the clinical characteristics among these 3 groups.
H&E analysis. Compared with the non-DM subjects, the total number of inflammatory cells per biopsy was higher in both DM groups (low-risk and high-risk; C: 83 ± 44, D: 143 ± 51, DN: 110 ± 39, P < .01; Figure 1 ). Similar results were observed for the number of inflammatory cells around vessels, a strong indication of inflammation (C: 8 ± 7, D: 17 ± 9, DN 14 ± 11, P < .05). Furthermore, there were no differences between type 1 and type 2 DM subjects in both the total number of inflammatory cells in the dermis (118 ± 47 vs 112 ± 40, respectively, P = ns) and the number of inflammatory cells around vessels (12 ± 9 vs 15 ± 11, P = ns).
The number of skin vessels also trended to be higher in the 2 diabetic groups when compared with the non-DM subjects but failed to reach statistical significance (C: 5.9 ± 2.9, D: 7.2 ± 2.2, DN: 6.8 ± 2.2, P = ns).
CD31 staining analysis. The number of CD31-positive proliferating endothelial cells around preexisting skin vessels was higher in both low-risk and high-risk DM subjects (C: 0 ± 0, D: 0.5 ± 0.5, DN: 0.5 ± 0.7, P < .05). The number of skin blood vessels per square millimeter was marginally higher in the 2 DM groups (C: 21 ± 9, D: 23 ± 7, DN 28 ± 12, P = .057). However, when the 2 DM groups were merged in 1 group, the number of vessels per square millimeter was higher in the DM group when compared with the non-DM subjects (27 ± 11 vs 21 ± 9, P < .05). There were no differences between type 1 and type 2 DM subjects in both proliferating cells (0.5 ± 0.6 vs 0.5 ± 0.7, respectively, P = ns) and the number of vessels per square millimeter (26 ± 12 vs 28 ± 11, P = ns).
There were no differences in the skin blood flow between the DM and non-DM subjects (C: 1.01 ± 0.23 [arbitrary units], D: 1.27 ± 0.41, DN: 1.05 ± 0.37, P = ns). Strong correlation was observed between the number of inflammatory cells around the vessels and the number of CD31-positive proliferating cells around preexisting skin vessels (r = .44, P < .0001) and the number of skin blood vessels per square millimeter (r = .24, P < .05). No correlation was observed between the number of vessels and skin blood flow.
Human Foot Biopsies
We have also investigated discarded skin specimens from the foot that were obtained during foot surgery from 7 non-DM healthy subjects (age 55 ± 18, 3 males) and 5 DM subjects (age 54 ± 16, 3 males). The results were similar to the ones observed in the forearm biopsies although they failed to reach statistical significance, most likely due to the small number of participants. Thus, H&E staining showed that DM patients trended to have higher number of skin blood vessels per biopsy when compared with the non-DM patients (45 ± 57 vs 27 ± 20, P = ns), while the number of CD45RO expressing cells around blood vessels, a marker of lymphocytes, also trended to be higher in the DM patients (88 ± 26 vs 77 ± 34, P = ns).
Rabbits
H&E analysis. The number of inflammatory cells per visual field from ear skin biopsies was higher in the DM animals when compared with the non-DM ones (2.2 ± 1.2 vs 0.8 ± 0.2, P < .02; (Figures 1 and 2A and B ). The number of blood vessels per visual field was also higher in the DM rabbits (5.5 ± 2.3 vs 2.6 ± 0.8, P < .01). When non-DM and DM animals were considered as 1 group, a strong correlation was observed between the number of inflammatory cells and skin vessels (r = .83, P < .0001).
CD31 staining analysis. The number of skin blood vessels trended to be higher in the DM rabbits compared with non-DM rabbits, although no statistical difference was observed, probably due to small number of tested animals (7.8 ± 4.0 vs 5.7 ± 3.1, P = ns).
Rats
H&E analysis. Inflammation, assessed as the number of inflammatory round cells, was higher in the skin of DM rats when compared with the non-DM rats (3.5 ± 0.8 vs 1.0 ± 0.3, P < .0001; Figures 1 and 2C and D) . The number of skin blood vessels was also higher in the DM rats compared with the non-DM rats (3.5 ± 0.9 vs 2.7 ± 0.6, P < .05).
CD31 staining analysis. The number of skin blood vessels identified by CD31 staining was increased in the DM rats when compared with the respective non-DM controls (5.3 ± 1.3 vs 3.8 ± 0.7, P < .01).
Mice H&E analysis. DM C57Bl6 mice had higher inflammatory cells per visual field than the non-DM C57Bl6 mice (3.8 ± 1.4 vs 1.3 ± 0.6, P < .0001; Figure 1 ). The number of blood vessels was also higher in the DM mice from the same strain (5.3 ± 1.4 vs 3.2 ± 1.1, P < .01). A strong correlation was observed between the number of inflammatory cells and vessels when non-DM and DM animals were grouped together (r = .79, P < .0001).
Compared with non-DM WBB6F1 mice, DM WBB6F1 mice also had higher number of inflammatory cells (12.1 ± 1.4 vs 8.6 ± 1.7, P < .0001) and higher number of skin blood vessels (3.8 ± 1.6 vs 1.4 ± 0.8, P < .001; Figures 1 and 2E and F). In addition, a correlation existed between these 2 parameters (r = .54, P < .05).
Finally, we compared differences between the 2 mice strains. Within the non-DM mice, WBB6F1 mice had higher number of inflammatory cells (8.6 ± 1.7 vs 1.3 ± 0.6, P < .0001) compared with C57Bl6 mice, while similar differences existed between the DM mice (12.1 ± 1.4 vs 3.2 ± 1.1, P < .0001). However, the number of skin blood vessels was lower in both the non-DM WBB6F1 mice when compared with the non-DM C57Bl6 mice (1.4 ± 0.8 vs 3.2 ± 1.1, P < .001) and the DM WBB6F1 compared with the DM C57Bl6 mice (3.8 ± 1.6 vs 5.3 ± 1.4, P = .05).
CD31 staining analysis. The number of CD31-positive endothelial cells per visual field was higher in the skin of the DM WBB6F1 mice when compared with their respective non-DM mice (6.8 ± 1.5 vs 3.8 ± 1.0, P < .01). The number of skin blood vessels was also increased in the DM group when compared with the non-DM group (3.7 ± 0.8 vs 1.8 ± 0.5, P < .01; Figure 2G and H).
Conclusions
The main finding of the present study is that there is increased skin inflammation in both human and animal models of diabetes. This is, to the best of our knowledge, the first study to report increased inflammation at the skin level in both human and experimental diabetes. In addition, we have observed an increase in the number of skin blood vessels in various animal models of experimental diabetes that is similar to the one observed in human diabetes. Finally, strong correlation was observed between the blood vessel density and inflammatory cell infiltration in both human and animal models of diabetes. Diabetes, especially type 2, and obesity are associated with increased systemic inflammation, as described by the elevated circulating inflammatory cytokines. 6, 7 In addition, inflammation in the adipose tissue has been proposed as one of the main factors that lead to the development of insulin resistance and type 2 diabetes. 8, 9 However, there is limited information regarding inflammation at the skin level. A previous study from our unit was one of the first to describe increased number of inflammatory cells in the dermis, especially around hair follicles and blood vessels constituting a specific sign of inflammation, in diabetes. 3 In the present article, we have expanded these observations and have shown that these changes are present in both nonneuropathic and neuropathic patients. Of interest, the present findings are in contrast with previous studies from our group that have indicated that systemic inflammation, assessed by the measurement of serum inflammatory cytokines, is present only in diabetic patients with neuropathy but is absent in diabetic patients without neuropathy. 10 These results indicate that in diabetes, skin inflammation probably manifests before the development of systemic inflammation and need further investigation.
An increase was also noticed in the endothelial cells proliferating around preexisting skin blood vessels and the density of skin blood vessels in the diabetic patients but there were no changes in the skin blood flow. These results suggest that although there is increased endothelial cell proliferation and new vessel formation, this does not result in an increase of functional vessels that can increase skin blood flow. To the best of our knowledge, there are no previous reports regarding changes in skin blood vessels in diabetes. Previous studies have reported either reduced density of functional capillaries in subjects with metabolic syndrome 11, 12 or no changes in subjects with impaired glucose tolerance and type 2 diabetes. 13 Furthermore, our previous studies have shown impaired endothelial and smooth muscle function in the microcirculation resulting in impaired vasodilation in subjects with prediabetes and diabetic subjects with or without complications. 4, 14 These data indicate that although blood vessel density is increased, the functional capacity of these vessels, especially under conditions of stress, remains limited and more studies are required to further explore this finding.
The possible mechanisms that are involved in the observed increased skin blood vessel density are not well understood. Inflammation is known to promote angiogenesis and may play a major role in the observed results. 15, 16 Previous studies in obese subjects have also shown an increase in serum vascular endothelial growth factor and have led to the hypothesis that adipocytes produce angiogenic factors that stimulate neovascularization, which in turn plays an important role in allowing fat mass expansion. [17] [18] [19] Further studies will be required to investigate whether similar mechanisms can also affect angiogenesis at the skin level.
No differences were observed in both skin inflammation and skin vessel changes between type 1 and 2 diabetic subjects. As expected, the duration of diabetes was longer in the type 1 patients although it was considerably long in both groups. Nonetheless, these results indicate that skin changes are similar in both types of diabetes of long duration.
Increased inflammatory cell infiltration and increased blood vessel density were also observed in the skin of various experimental animal models of diabetes that are typically used in wound healing studies. We opted to study all these animal models because there is a lack of a single model that satisfactorily represents the human condition representing skin and wound healing changes. Current consensus is that findings should be confirmed in more than one animal model. The rabbit ear model has the advantages that similarly to human wounds, rabbit wounds heal mainly by re-epithelialization and allows the introduction of ischemia and neuropathy by ligating the central and the rostral ear artery and the central and rostral nerves, respectively. 20, 21 On the other hand, rodents heal mainly by contraction but are easier to manipulate and also allow the study of various genetically engineered models. Despite the above differences, similar results were observed for both skin inflammation and skin blood vessel density in these various models. The consistency of these findings in different species provides strong validation of the observed results. This can enable the conduction of future mechanistic studies to further understand the underlying mechanisms leading to the observed results in more than one animal model.
The number of inflammatory cells was clearly increased in all studied diabetic animal models, indicating that skin inflammation is prominent in these diabetic models. On the other hand, the changes in the skin vessel density, although heading in the same direction, did not achieve statistical significance in all models. Thus, no statistical significance was reached in the H&E analysis in humans despite significant differences in CD31 analysis. No differences were observed in the CD31 analysis in the rabbit ear, despite the existence of such difference when H&E analysis was employed. The main reason for these findings was that the skin vessel changes were less prominent than the inflammatory cell changes, and larger numbers of human and large animals would be required to reach statistical significance in all measurements. Despite these limitations, the specificity of CD31 analysis and the confirmation it provided that the structures observed by H&E analysis are blood vessels clearly indicate an increase in the skin blood vessel numbers in diabetic humans, rats, and mice and a similar, but less prominent, increase in diabetic rabbits. Given the logistic limitations such as the number of animals that can be studied, mainly due to costs and availability of animal facilities, our results suggest that mice may be the preferred animal model to study diabetes-related changes in the skin vessels.
The study has its limitations. Only type 1 diabetes animal models were studied. However, there are no major differences in the wound healing processes between type 1 and 2 animal models, and the models presented in this study are the commonly used models of diabetic wound healing. Also, no differences were observed regarding inflammation or vascular density at the skin level between type 1 and type 2 diabetic subjects. Therefore, we believe that the choice of animal models should not influence the observed results. Moreover, no statistical differences were reached in the human foot skin specimens. The main reason for this was the small subject numbers. It should be noted that due to obvious risks, no biopsies were obtained from the feet of diabetic subjects. Instead, the feet skin samples from diabetic subjects came from discarded tissues during various operations. However, the fact that the observed results from the discarded skin of the foot were similar to those from the skin biopsies of the forearm clearly indicate that changes at both sites in diabetic subjects are similar and supports the hypothesis of a generalized effect of diabetes. In addition to the above, the inflammatory cells were identified by H&E staining, a commonly used technique that lacks specificity. However, our previous studies using CD45RO staining have clearly indicated that our analysis specifically evaluates inflammatory cells in the human biopsies. 3 Furthermore, specific precautions, described in the Methods section, were taken in the animal biopsies to exclude other types of cells, mainly transversely cut fibroblasts and/or fibrocytes that appear round, despite the fact that they are ovoid or spindle shaped. We therefore strongly believe that the observed cells were inflammatory and that there were no biases that could have affected our results.
In summary, our results indicate that there is increased number of skin inflammatory cells and blood vessels in human diabetes and also in rodent and the rabbit ear models of experimental diabetes.
